<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14894">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01828008</url>
  </required_header>
  <id_info>
    <org_study_id>BT-004</org_study_id>
    <nct_id>NCT01828008</nct_id>
  </id_info>
  <brief_title>Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas</brief_title>
  <acronym>CIK</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Han weidong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <authority>China: General Hospital of PLA</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the safety and efficacy of CD20 antibody usage followed by CIK transfusion in
      refractory and/or chemoresistant lymphomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autologous CIK transfusion within 3 days post CD20 antibody treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>disease free survival</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lymphomas</condition>
  <eligibility>
    <study_pop>
      <textblock>
        the patients with CD20-positive Lymphomas
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - diagnosed as B-cell lymphoma with CD20 positiveness, and need to therapy

        Exclusion Criteria:

        - to refuse the therapy and need not tolerate the therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>April 9, 2013</lastchanged_date>
  <firstreceived_date>April 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Han weidong</investigator_full_name>
    <investigator_title>combination of anti-CD20 with CIK for refractory lymphomas</investigator_title>
  </responsible_party>
  <keyword>Mabthera</keyword>
  <keyword>cytokine induced killer cell</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
